Alexion Pharma (ALXN) Tops Q4 EPS by 20c, FY Guidnace Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharmaceuticals (ALXN) PT Lowered to $161 at Deutsche Bank Following 4Q Report
February 9, 2018 7:22 AM ESTDeutsche Bank lowered its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $161.00 (from $163.00) while maintaining a Buy rating following the company's 4Q earnings report. Alexion reported total sales that topped consensus expectations (+3.4% vs Street) with the beat largely driven primarily by volume growth across all... More
